Neuroprotective compounds conjugated to specific glycan structures would selectively accumulate in tau-containing vesicles, providing targeted delivery of therapeutic agents. This Trojan horse approach exploits the unique glycan signatures as delivery addresses.
Auto-built from this analysis's top knowledge-graph edges.
graph TD
ST6GAL1["ST6GAL1"] -->|regulates| sialylation["sialylation"]
ST6GAL1_1["ST6GAL1"] -->|catalyzes| sialylation_2["sialylation"]
ST6GAL1_3["ST6GAL1"] -->|associated with| tau_spreading["tau_spreading"]
style ST6GAL1 fill:#ce93d8,stroke:#333,color:#000
style sialylation fill:#ffd54f,stroke:#333,color:#000
style ST6GAL1_1 fill:#ce93d8,stroke:#333,color:#000
style sialylation_2 fill:#4fc3f7,stroke:#333,color:#000
style ST6GAL1_3 fill:#ce93d8,stroke:#333,color:#000
style tau_spreading fill:#4fc3f7,stroke:#333,color:#000No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for ST6GAL1 yet. Search RCSB →
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for ST6GAL1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF a neuroprotective compound is conjugated to ST6GAL1-preferred glycan structures (α-2,6-linked sialic acid) and applied to neurons from a tauopathy mouse model (PS19), THEN it will accumulate at ≥2- | Subcellular fractionation and immunofluorescence will show glycan-conjugated compound colocalization with tau-positive vesicles at 2-fold or greater enrichment | — no observation — | pending | 0.45 |
| IF ST6GAL1 is genetically silenced using CRISPR interference in SH-SY5Y cells with inducible tau overexpression, THEN the selectivity of glycan-conjugated drug accumulation in tau-positive vesicles wi | ST6GAL1 knockdown will reduce tau-vesicle selectivity index by ≥60%, with no change in overall cell viability, as quantified by high-content imaging | — no observation — | pending | 0.40 |